

VBC Release Highlights

June 20, 2025

Practice InsightsSM is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard will be updated to reflect the below refinement(s):

Measure	Description	Practice Impact
<p><u>PIMSH 17: Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure)</u></p>	<p>This is a new QCDR measure gauging the use of GCSF in patients receiving low-risk chemotherapy.</p> <p>Denominator includes all patients with cancer (solid tumors only) receiving their first cycle of low-risk chemotherapy within the measurement period with a qualifying encounter during the measurement period.</p> <p>Requires one qualifying encounter during the measurement period.</p> <p>Denominator Exclusion:</p> <ul style="list-style-type: none"> • Patients on clinical trial at the time of treatment. <p>Numerator:</p> <ul style="list-style-type: none"> • Patients ordered GCSF within 7 days following receipt of chemotherapy. • Numerator guidance provided to detail ordered versus administered scenarios. 	<p>Establish a numerator and denominator for this new measure.</p> <p>New measures in their first year of reporting have a 7-point benchmark floor if data completeness of 75% is met.</p>
<p><u>MIPS 144: Pain Care Plan</u></p>	<p>Denominator Criteria 1:</p> <ul style="list-style-type: none"> • Removed telehealth modifier 95. • Added new Cancer 	<p>Minimal decrease in denominator and/or numerator count.</p>

Measure	Description	Practice Impact
	<p>Diagnosis ICD-10 codes.</p> <ul style="list-style-type: none"> • Added new Encounter & Performance CPT codes. <p>Denominator Criteria 2:</p> <ul style="list-style-type: none"> • Added new Cancer Diagnosis ICD-10 codes. • Removed all telehealth modifier criteria. 	

EOM Performance Measures Dashboard

The EOM Performance Measures Dashboard will be updated to reflect the below refinement(s):

Measure	Description	Practice Impact
<u>EOM-4A: Pain Intensity Quantified</u>	<p>Denominator Criteria 1:</p> <ul style="list-style-type: none"> • Added new Cancer Diagnosis ICD-10 codes • Added new Encounter & Procedure CPT codes • Removed Telehealth Modifier 95 <p>Denominator Criteria 2:</p> <ul style="list-style-type: none"> • Added new Cancer Diagnosis ICD-10 codes • Removed all telehealth modifier criteria 	<p>Minimal decrease in denominator and/or numerator count.</p>

Status of Dashboard Updates for 2025

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.

Measure	Description
MIPS Quality Measures Dashboard	
MIPS #001	Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure)
MIPS #047	Advance Care Plan
MIPS #130	Current Medications Documentation
MIPS #143	Pain Intensity Quantified
MIPS #144	Pain Care Plan
MIPS #226	Tobacco Screening and Cessation
MIPS #236	Controlling High Blood Pressure
MIPS #238	Use of High-Risk Medications in Older Adults (Inverse Measure)
MIPS #374	Closing the Referral Loop
MIPS #450	Appropriate Treatment for Patients with Stage I (T1c) III Her2 Positive Breast Cancer
MIPS #451	RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal

Measure	Description
	Antibody Therapy
MIPS #453	Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)
MIPS #457	Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days
MIPS #462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
MIPS #487	Screening for Social Drivers of Health
PIMSH #1	Advance Care Planning in Metastatic Disease
PIMSH #9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH #10	Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH #13	Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy

Measure	Description
PIMSH #15	Antiemetic Therapy for Low-and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH #16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center
PIMSH #17	Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure)
EOM Performance Measures Dashboard	

EOM-4A

Pain Intensity Quantified